In the recent CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) trial, canakinumab, a monoclonal antibody against IL-1β, significantly prevented recurrent CV events among patients with a prior myocardial infarction (MI) and high levels of pro-inflammatory biomarkers28. Here, IL1B is linked to deep vein thrombosis.